pmc logo image
Logo of bmjBMJ helping doctors make better decisionsSearchLatest content

Formats:

BMJ. 1989 April 29; 298(6681): 1147–1152.
PMCID: PMC1836358
Do antihypertensive drugs precipitate diabetes in predisposed men?
E. T. Skarfors, H. O. Lithell, I. Selinus, and H. Aberg
Department of Geriatrics, Uppsala University, Sweden.
Abstract
OBJECTIVE--To evaluate the influence of antihypertensive treatment and metabolic characteristics on the development of diabetes mellitus in middle aged men. DESIGN--Prospective study over an average of nine years. SETTING--Community based health survey of middle aged men carried out at the University of Uppsala. SUBJECTS--Seventy three hypertensive men aged 49-54 and 65 normotensive controls matched for body mass index, glucose disappearance rate (k value) at an intravenous glucose tolerance test, and serum triglyceride and cholesterol concentrations. INTERVENTIONS--Hypertensive group was treated with beta blockers, thiazides, hydralazine, or combinations of these drugs. Treatment was not randomised. MEASUREMENTS and MAIN RESULTS--Intravenous glucose tolerance, fasting blood glucose and serum lipid and insulin concentrations, body weight and height, three skinfold measurements, and blood pressure were recorded both during an initial health screening survey in 1970-3 and at a follow up survey in 1980-3. In the period between the two surveys 12 hypertensive men and two controls developed diabetes. Review of values obtained at the initial survey showed that the hypertensive men who developed diabetes or impaired glucose tolerance could be distinguished from those hypertensive men who did not by virtue of a higher fasting serum insulin concentration (26.1 v 15.2 mU/l (confidence interval of difference -15.2 to -6.2)), a lower peak serum insulin concentration (78.9 v 94.3 mU/l (confidence interval of difference -1.1 to 41.1)), and a lower k value (1.29 v 1.68 (confidence interval of difference -0.02 to 0.68)). The insulin index (peak insulin concentration divided by fasting insulin concentration), however, decreased significantly in the hypertensive men over time irrespective of whether they developed diabetes but did not change in the controls. Furthermore, the serum triglyceride concentration increased in the treated group and decreased in the controls. CONCLUSION--A severalfold difference in the incidence of diabetes between treated hypertensive and non-treated, normotensive men may be a consequence of the treatment, which may be particularly deleterious in men predisposed to diabetes.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Bengtsson C, Blohmé G, Lapidus L, Lindquist O, Lundgren H, Nyström E, Petersen K, Sigurdsson JA. Do antihypertensive drugs precipitate diabetes? Br Med J (Clin Res Ed). 1984 Dec 1;289(6457):1495–1497. [PubMed]
  • Ames RP, Hill P. Increase in serum-lipids during treatment of hypertension with chlorthalidone. Lancet. 1976 Apr 3;1(7962):721–723. [PubMed]
  • Tanaka N, Sakaguchi S, Oshige K, Niimura T, Kanehisa T. Effect of chronic administration of propranolol on lipoprotein composition. Metabolism. 1976 Oct;25(10):1071–1075. [PubMed]
  • Waal-Manning HJ, Simpson FO. Beta-blockers and lipid metabolism. Br Med J. 1977 Sep 10;2(6088):705–705. [PubMed]
  • Day JL, Simpson N, Metcalfe J, Page RL. Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Br Med J. 1979 Jan 13;1(6156):77–80. [PubMed]
  • Lasser NL, Grandits G, Caggiula AW, Cutler JA, Grimm RH, Jr, Kuller LH, Sherwin RW, Stamler J. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. Am J Med. 1984 Feb 27;76(2A):52–66. [PubMed]
  • Aberg H, Hadstrand H, Lithell H. Blood pressure control in a middle-aged male population. A 6-9 year follow-up with special reference to the problem of non-responders. Acta Med Scand. 1980;208(6):467–471. [PubMed]
  • Berglund G, Larsson B, Andersson O, Larsson O, Svärdsudd K, Björntorp P, Wilhelmsen L. Body composition and glucose metabolism in hypertensive middle-aged males. Acta Med Scand. 1976;200(3):163–169. [PubMed]
  • IKKOS D, LUFT R. On the intravenous glucose tolerance test. Acta Endocrinol (Copenh). 1957 Jul;25(3):312–334. [PubMed]
  • BURSTEIN M, SAMAILLE J. [On a rapid determination of the cholesterol bound to the serum alpha- and beta-lipoproteins.]. Clin Chim Acta. 1960 Jul;5:609. [PubMed]
  • Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J. 1986 Aug;112(2):432–437. [PubMed]
  • Aberg H, Lithell H, Selinus I, Hedstrand H. Serum triglycerides are a risk factor for myocardial infarction but not for angina pectoris. Results from a 10-year follow-up of Uppsala primary preventive study. Atherosclerosis. 1985 Jan;54(1):89–97. [PubMed]
  • Pyöräla K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care. 1979 Mar–Apr;2(2):131–141. [PubMed]
  • Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia. 1980 Sep;19(3):205–210. [PubMed]
  • Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care. 1979 Mar–Apr;2(2):154–160. [PubMed]